Shares of Diageo plc (NYSE:DEO – Get Free Report) have been given a consensus recommendation of “Reduce” by the eight analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company.
Several equities analysts have recently issued reports on DEO shares. The Goldman Sachs Group lowered Diageo from a “neutral” rating to a “sell” rating in a research report on Friday, July 12th. Bank of America raised shares of Diageo from a “neutral” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, Royal Bank of Canada raised shares of Diageo from an “underperform” rating to a “sector perform” rating in a research report on Monday, August 12th.
Read Our Latest Stock Analysis on DEO
Hedge Funds Weigh In On Diageo
Diageo Price Performance
Diageo stock opened at $123.57 on Tuesday. The business’s 50-day simple moving average is $133.44 and its 200 day simple moving average is $132.93. The company has a quick ratio of 0.55, a current ratio of 1.53 and a debt-to-equity ratio of 1.62. The stock has a market cap of $68.74 billion, a price-to-earnings ratio of 17.63, a P/E/G ratio of 3.54 and a beta of 0.71. Diageo has a 12-month low of $119.48 and a 12-month high of $161.64.
Diageo Company Profile
Diageo plc, together with its subsidiaries, engages in the production, marketing, and sale of alcoholic beverages. The company offers scotch, gin, vodka, rum, raki, liqueur, wine, tequila, Chinese white spirits, cachaça, and brandy, as well as beer, including cider and flavored malt beverages. It also provides Chinese, Canadian, Irish, American, and Indian-Made Foreign Liquor whiskies, as well as flavored malt beverages, ready to drink, and non-alcoholic products.
Featured Articles
- Five stocks we like better than Diageo
- Investing In Preferred Stock vs. Common Stock
- Intel: Is Now the Time to Be Brave?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is Insider Trading? What You Can Learn from Insider Trading
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Diageo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diageo and related companies with MarketBeat.com's FREE daily email newsletter.